Theranostics Momentum Mediso has recently launched theranostic capable SPECT/CT solutions (TheraMAX) and theranostic imaging capabilities, signaling strong potential to upsell integrated imaging workflows and companion diagnostics for nuclear medicine departments.

Multimodality Strength With four imaging modalities (SPECT, PET, CT, MRI) and FDA-cleared multimodality processing software, Mediso sits well to cross-sell integrated systems and cross-modality workflow software to labs expanding into comprehensive molecular imaging.

Global Footprint Direct and distributor network reach across 100+ countries and over 1,750 installed systems indicate sizable market access and renewal opportunities for service contracts, parts, and upgrade programs in diverse regions.

Innovation Pipeline Active R&D activity including next-gen MRI spectrometer spinScan and recent IP acquisitions suggests ongoing product lifecycle extensions, enabling targeted upgrade offers and trade-in programs to existing Mediso customers.

Regulatory Readiness FDA clearance achieved for multimodality image processing software indicates strong regulatory engagement; leverage this to position compliant, enterprise-wide QA, reporting, and data-integrity solutions to radiology and research institutions pursuing scalable deployments.